Literature DB >> 28780579

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.

Iryna Schlackow1, Seamus Kent1, William Herrington2, Jonathan Emberson2, Richard Haynes2, Christina Reith2, Christoph Wanner3, Bengt Fellström4, Alastair Gray1, Martin J Landray2, Colin Baigent2,5, Borislava Mihaylova1.   

Abstract

OBJECTIVE: To present a long-term policy model of cardiovascular disease (CVD) in moderate-to-advanced chronic kidney disease (CKD).
METHODS: A Markov model with transitions between CKD stages (3B, 4, 5, on dialysis, with kidney transplant) and cardiovascular events (major atherosclerotic events, haemorrhagic stroke, vascular death) was developed with individualised CKD and CVD risks estimated using the 5 years' follow-up data of the 9270 patients with moderate-to-severe CKD in the Study of Heart and Renal Protection (SHARP) and multivariate parametric survival analysis. The model was assessed in three further CKD cohorts and compared with currently used risk scores.
RESULTS: Higher age, previous cardiovascular events and advanced CKD were the main contributors to increased individual disease risks. CKD and CVD risks predicted by the state-transition model corresponded well to risks observed in SHARP and external cohorts. The model's predictions of vascular risk and progression to end-stage renal disease were better than, or comparable to, those produced by other risk scores. As an illustration, at age 60-69 years, projected survival for SHARP participants in CKD stage 3B was 13.5 years (10.6 quality-adjusted life years (QALYs)) in men and 14.8 years (10.7 QALYs) in women. Corresponding projections for participants on dialysis were 7.5 (5.6 QALYs) and 7.8 years (5.4 QALYs). A non-fatal major atherosclerotic event reduced life expectancy by about 2 years in stage 3B and by 1 year in dialysis.
CONCLUSIONS: The SHARP CKD-CVD model is a novel resource for evaluating health outcomes and cost-effectiveness of interventions in CKD. TRIAL REGISTRATION NUMBER: NCT00125593 and ISRCTN54137607; Post-results. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  CKD progression; cardiovascular risk; chronic kidney disease; life expectancy; markov model

Mesh:

Year:  2017        PMID: 28780579      PMCID: PMC5749372          DOI: 10.1136/heartjnl-2016-310970

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  25 in total

Review 1.  EuroQol: the current state of play.

Authors:  R Brooks
Journal:  Health Policy       Date:  1996-07       Impact factor: 2.980

2.  Validation of the atherosclerotic cardiovascular disease Pooled Cohort risk equations.

Authors:  Paul Muntner; Lisandro D Colantonio; Mary Cushman; David C Goff; George Howard; Virginia J Howard; Brett Kissela; Emily B Levitan; Donald M Lloyd-Jones; Monika M Safford
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

3.  Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts.

Authors:  Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh
Journal:  Kidney Int       Date:  2011-02-02       Impact factor: 10.612

4.  2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  David C Goff; Donald M Lloyd-Jones; Glen Bennett; Sean Coady; Ralph B D'Agostino; Raymond Gibbons; Philip Greenland; Daniel T Lackland; Daniel Levy; Christopher J O'Donnell; Jennifer G Robinson; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Paul Sorlie; Neil J Stone; Peter W F Wilson; Harmon S Jordan; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

Review 5.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

6.  A predictive model for progression of chronic kidney disease to kidney failure.

Authors:  Navdeep Tangri; Lesley A Stevens; John Griffith; Hocine Tighiouart; Ognjenka Djurdjev; David Naimark; Adeera Levin; Andrew S Levey
Journal:  JAMA       Date:  2011-04-11       Impact factor: 56.272

7.  A health policy model of CKD: 1. Model construction, assumptions, and validation of health consequences.

Authors:  Thomas J Hoerger; John S Wittenborn; Joel E Segel; Nilka R Burrows; Kumiko Imai; Paul Eggers; Meda E Pavkov; Regina Jordan; Susan M Hailpern; Anton C Schoolwerth; Desmond E Williams
Journal:  Am J Kidney Dis       Date:  2010-02-08       Impact factor: 8.860

8.  Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts.

Authors:  Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew Levey; Paul de Jong; Ron T Gansevoort; Marije van der Velde; Kunihiro Matsushita; Josef Coresh; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Ron T Gansevoort; Andrew Levey; Meguid El-Nahas; Kai-Uwe Eckardt; Bertram L Kasiske; Toshiharu Ninomiya; John Chalmers; Stephen Macmahon; Marcello Tonelli; Brenda Hemmelgarn; Frank Sacks; Gary Curhan; Allan J Collins; Suying Li; Shu-Cheng Chen; K P Hawaii Cohort; Brian J Lee; Areef Ishani; James Neaton; Ken Svendsen; Johannes F E Mann; Salim Yusuf; Koon K Teo; Peggy Gao; Robert G Nelson; William C Knowler; Henk J Bilo; Hanneke Joosten; Nanno Kleefstra; K H Groenier; Priscilla Auguste; Kasper Veldhuis; Yaping Wang; Laura Camarata; Beverly Thomas; Tom Manley
Journal:  Kidney Int       Date:  2011-02-09       Impact factor: 10.612

9.  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.

Authors:  Christoph Wanner; Vera Krane; Winfried März; Manfred Olschewski; Johannes F E Mann; Günther Ruf; Eberhard Ritz
Journal:  N Engl J Med       Date:  2005-07-21       Impact factor: 91.245

10.  CKD and the risk of incident cancer.

Authors:  William T Lowrance; Juan Ordoñez; Natalia Udaltsova; Paul Russo; Alan S Go
Journal:  J Am Soc Nephrol       Date:  2014-05-29       Impact factor: 10.121

View more
  7 in total

1.  Use of Measures of Inflammation and Kidney Function for Prediction of Atherosclerotic Vascular Disease Events and Death in Patients With CKD: Findings From the CRIC Study.

Authors:  Richard L Amdur; Harold I Feldman; Elizabeth A Dominic; Amanda H Anderson; Srinivasan Beddhu; Mahboob Rahman; Myles Wolf; Muredach Reilly; Akinlolu Ojo; Raymond R Townsend; Alan S Go; Jiang He; Dawei Xie; Sally Thompson; Matthew Budoff; Scott Kasner; Paul L Kimmel; John W Kusek; Dominic S Raj
Journal:  Am J Kidney Dis       Date:  2018-12-10       Impact factor: 8.860

2.  Prognostic Factors of Fatal and Nonfatal Cardiovascular Events in Patients With Type 2 Diabetes: The Role of Renal Function Biomarkers.

Authors:  Stefanos Roumeliotis; Vassilios Liakopoulos; Athanasios Roumeliotis; Aikaterini Stamou; Stylianos Panagoutsos; Graziella D'Arrigo; Giovanni Tripepi
Journal:  Clin Diabetes       Date:  2021-04

3.  Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis.

Authors:  Miriam Brazzelli; Lorna Aucott; Magaly Aceves-Martins; Clare Robertson; Elisabet Jacobsen; Mari Imamura; Amudha Poobalan; Paul Manson; Graham Scotland; Callum Kaye; Simon Sawhney; Dwayne Boyers
Journal:  Health Technol Assess       Date:  2022-01       Impact factor: 4.106

Review 4.  Incorporating Scoring Risk Models for Care Planning of the Elderly with Chronic Kidney Disease.

Authors:  Josefina Santos; Isabel Fonseca
Journal:  Curr Gerontol Geriatr Res       Date:  2017-11-28

5.  Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.

Authors:  Iryna Schlackow; Seamus Kent; William Herrington; Jonathan Emberson; Richard Haynes; Christina Reith; Rory Collins; Martin J Landray; Alastair Gray; Colin Baigent; Borislava Mihaylova
Journal:  Kidney Int       Date:  2019-03-12       Impact factor: 10.612

6.  The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.

Authors:  Seamus Kent; Frauke Becker; Talitha Feenstra; An Tran-Duy; Iryna Schlackow; Michelle Tew; Ping Zhang; Wen Ye; Shi Lizheng; William Herman; Phil McEwan; Wendelin Schramm; Alastair Gray; Jose Leal; Mark Lamotte; Michael Willis; Andrew J Palmer; Philip Clarke
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

Review 7.  Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design.

Authors:  Daniel M Sugrue; Thomas Ward; Sukhvir Rai; Phil McEwan; Heleen G M van Haalen
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.